Lawmakers were told that early-life exposure to a bacterial toxin is now a leading suspect behind the increasing incidence of bowel cancer in adults under 50.
In many nations, early-onset bowel cancer cases have doubled over the past 20 years. Although growing obesity rates and declining physical activity contribute to the trend, scientists say additional factors are likely at play.
Dr. Karl Smith-Byrne, a senior molecular epidemiologist at the University of Oxford, informed the Commons science and technology committee that established risk factors—including obesity, smoking, and alcohol—account for only about half of the colorectal cancer cases diagnosed by physicians.
He added that it seems implausible to attribute the surge in early-onset bowel cancer solely to risk factors already known to researchers.
Researchers last year identified colibactin—a toxin produced by certain E. coli variants in the gut—as a potential driver of early-onset colorectal cancer. Distinctive mutations linked to the toxin appeared three times more frequently in tumors from patients under 40 than in those from patients over 70.
Scientists are actively investigating whether colibactin actually causes bowel cancer, though further research is required. “That is likely the leading explanation right now,” Smith-Byrne told members of parliament.
Professor Mike Stratton of the Sanger Institute, who did not attend the hearing, said colibactin triggers mutations in some children but not others, with evidence of such changes appearing in infancy. His research indicates that by age 10, affected children may carry a “mutational burden” comparable to that of a 50-year-old.
“If it is causing mutations, it is doing so during a sensitive early-life window, potentially giving that person’s colon or rectum a head start toward becoming cancerous or developing tumors,” said Smith-Byrne, himself a survivor of early-onset rectal cancer.
Some researchers suspect that certain E. coli variants—typically harmless gut residents—have evolved in recent decades to produce colibactin. Professor Elio Riboli, a cancer epidemiologist at Imperial College London, told the committee: “This colibactin is essentially found in people born after 1960. Something has changed in the E. coli bacteria… There must have been a mutation, and a new bacterial strain has emerged.”
Bowel cancer ranks as the third most common cancer worldwide, representing roughly one in ten cases. While it remains far more prevalent among those over 50, global data show diagnoses are climbing steeply in younger populations.
Professor Helen Coleman, a cancer epidemiologist at Queen’s University Belfast, told MPs that colibactin is “the first new clue we’ve had in quite some time,” though its potential role in bowel cancer remains under investigation.
“Even though we are discussing adults diagnosed between ages 18 and 49, the exposure likely occurs very early in life,” she said. “It could involve something encountered in early childhood, or even during the prenatal period, which makes it extremely difficult to study.”
Riboli emphasized that while scientists must continue identifying the unknown drivers of various cancers, people should reduce risks that are already well understood. In the UK and US, smoking and alcohol consumption are declining, but obesity is rising and physical activity is decreasing. “The quickest gains could come from applying what we already know,” he said. “We could prevent roughly 60% of current cancers, but society is not putting that knowledge into practice.”
Also Read
- Post-U.S. Midterm Trans-Atlantic Defense: A Strategic Dialogue
- Mortgage Rates Slip Wednesday, but 7%-Plus Averages Keep Buyer Budgets Tight
- St. Peter’s Basilica Celebrates Four Centuries as Catholicism’s Spiritual Epicenter
- House Democrats Nominate Hakeem Jeffries for Speaker, Setting Up Historic Leadership Bid

